Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in Acute Monocytic Leukemia
NCT07512700Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute monocytic leukemia (AML-M5) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Composite Complete Remission Rate. Started Sep 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute monocytic leukemia (AML-M5)
Beyond the preview
Go deeper on NCT07512700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512700.